Aridis touts positive preclinical results for COVID-19 mAb treatment

By The Science Advisory Board staff writers

October 19, 2020 -- Anti-infective therapies firm Aridis Pharmaceuticals has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.

The company tested its candidate, AR-711, in a preclinical study on Syrian hamsters infected with SARS-CoV-2. The infected hamsters received a single exposure of inhaled AR-711 liquid aerosols, which eliminated detectable viral loads at all dose levels tested, including just 0.03 mg/kg, according to Aridis.

The therapeutic worked at lower doses than injected COVID-19 antibodies, the company noted. Aridis said the candidate's potency may be a result of its direct delivery to the lungs.

Aridis used a proprietary formula to stabilize the candidate and allow for delivery with a commercial nebulizer. This format could allow for wide-scale use in a variety of nonhospital settings, the company noted.

Aridis discovered the antibody from convalescent plasma in patients with COVID-19 and engineered it to last up to 12 months in blood, according to the company. It works by targeting the receptor-binding domain region in the novel coronavirus and emerging variants.

Ionis' inhaled antisense drug shows promise as CF treatment
Ionis Pharmaceuticals has released positive data from a clinical trial evaluating IONIS-ENAC-2.5Rx, an investigational antisense medicine designed to...
Ampio granted IND for inhaled COVID-19 therapy
Ampio Pharmaceuticals has received investigational new drug (IND) authorization from the U.S. Food and Drug Administration, allowing it to conduct additional...
Partner Therapeutics begins COVID-19 clinical trial for Leukine
Partner Therapeutics has enrolled the first patient in its iLeukPulm clinical trial, a randomized phase II study of inhaled sargramostim (Leukine) in...
COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...
Are masks effective at preventing the spread of SARS-CoV-2?
Contradictory messages over the best methods to limit the spread of SARS‑CoV‑2 have been shared with the public in past months. This has prompted...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter